browse Browse

pac.dog pac.dog / Lobbying

1st Quarter - Report · 2026

Filing UUID
61f1f5cb-cc95-4d27-924d-b039ff24d862
Type
Q1 — 1st Quarter - Report
Period
first_quarter
Year
2026
Posted
2026-04-21 00:08:05
Income (reported)
—
Expenses (reported)
$1,150,000
Expenses method
A
Filing document
Open on lda.senate.gov

Registrant (lobbying firm)

CENCORA, INC.

Pharmaceutical Distributor

Contact
DANIEL GRAINGER
Phone
2021343501
Address
zip:20003, city:WASHINGTON, state:DC, street:412 1st Street SE, Suite 200

Client

CENCORA, INC.

State
DC
Country
US
Government-entity client
false
Effective date
2005-01-05

Issues lobbied + lobbyists

MMM — Medicare/Medicaid

Ensuring Community Access to Pharmacist Services Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426) Inflation Reduction Act implementation, including impact on Pharmacy & Physician Reimbursement Extend payment increase under CMS FY 2026 Medicare's Part B physician fee schedule. Protecting Patient Access to Cancer and Complex Therapies Act 2025 (H.R.4299) Reimbursement policies impacting drug shortages Part B drug pricing changes Preventing and Mitigating Generic Drug Shortages CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; White House Office

PHA — Pharmacy

Preventing and Mitigating Generic Drug Shortages Ensuring Seniors Access to Critical Medications Act (H.R. 3164)/Equitable Community Access to Pharmacist Services Act (S.2426)- Impacts to pharmacy Part D drug pricing in Inflation Reduction Act (IRA) Support for Fair Pharmacy Reimbursement

Lobbyists:

Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; SENATE; White House Office

HCR — Health Issues

Essential Medicines Strategic Stockpile Department of Defense Essential Medicines Strategic Stockpile Prescription Information Modernization Act (H.R.4132/S.2027) Mitigation of Drug Shortages Pharmaceutical supply chain resilience National Defense Authorization Act FY2026 (NDAA) Supply Chain Resiliency Most Favored Nation drug pricing proposals Direct to Consumer proposals CMS Medicare Part B Physician Fee Schedule Rule Break Up Big Medicine Act (S. 3822) CMS FY 2026 Medicares Part B Physician Fee Schedule: Proposed Changes to Bonafide Service Fees Role and value of community specialty physicians and MSOs

Lobbyists:

Government entities lobbied: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; White House Office

pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.